DNMT Inhibitors Increase Methylation in the Cancer Genome

DNMT Inhibitors Increase Methylation in the Cancer Genome

DNA methyltransferase inhibitors (DNMTi) decitabine and azacytidine are approved therapies for myelodysplastic syndrome and acute myeloid leukemia, and their combinations with other anticancer agents are being tested as therapeutic options for multiple solid cancers such as colon, ovarian, and lung...

Full description

Bibliographic Details
Main Authors: Anil K. Giri, Tero Aittokallio
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Series:Frontiers in Pharmacology
Subjects:
DNA methyltransferase inhibitors
decitabine
azacytidine
anticancer treatment
olfactory receptor pathway
alternative splicing
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00385/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00385/full

Similar Items